scispace - formally typeset
Journal ArticleDOI

Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges.

Reads0
Chats0
TLDR
This review describes the evolution of WHO guidelines for antiretroviral therapy (ART) in HIV-infected individuals, considering the key epidemiological, scientific, programmatic, and political changes over the last decade, and highlights the major trends for the management of the HIV disease in future guidelines revisions.
Abstract
PURPOSE OF REVIEW: This review describes the evolution of WHO guidelines for antiretroviral therapy (ART) in HIV-infected individuals considering the key epidemiological scientific programmatic and political changes over the last decade and highlights the major trends for the management of the HIV disease in future guidelines revisions. RECENT FINDINGS: In the last few years new evidence has emerged supporting the potential preventive benefit of ART in reducing HIV transmission. This together with the potential clinical benefits of earlier initiation of therapy has led to the consideration of the broader strategic use of ART taking into account the clinical and public health benefit and programmatic feasibility. SUMMARY: In 2002 WHO established its first guidelines for ART use primarily focused on a public health approach for resource-limited settings. These recommendations were updated in 2003 2006 and 2010 incorporating progressive changes reflecting progressive increase in the knowledge of HIV pathogenesis development of new drugs and diagnostics and increased experience of HIV treatment and prevention programs. The impact of several international political commitments and scale-up initiatives such as the 3 by 5 Initiative Universal Access targets and the Treatment 2.0 Strategy were also important drivers of the global response increasing the treatment coverage and catalyzing the necessary environment for the establishment of operational and programmatic components for an expanded and sustainable global response to HIV/AIDS.

read more

Citations
More filters
Journal ArticleDOI

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.

TL;DR: Compared to NVP, EFV is associated with a lower frequency of severe adverse events, in particular treatment discontinuations, which supports a move toward EFV-based therapy as the preferred first-line treatment regimen for HIV treatment within a public health approach.
Journal ArticleDOI

The future role of CD4 cell count for monitoring antiretroviral therapy

TL;DR: CD4 cell counts will continue to play an important part in initial decisions around ART initiation and clinical management, particularly for patients presenting late to care, and for treatment monitoring where viral load monitoring is restricted, however, in settings where both CD4 cell count and viral load testing are routinely available, countries should consider reducing the frequency.
Journal ArticleDOI

The evolving role of CD4 cell counts in HIV care.

TL;DR: The role of CD4 cell count in the management of people living with HIV is once again changing, most notably with a shift away from using CD4 assays to decide when to start antiretroviral therapy (ART) as mentioned in this paper.
Journal ArticleDOI

Emerging Technologies for Point-of-Care Management of HIV Infection

TL;DR: Challenges associated with HIV management in resource-constrained settings are discussed and the state-of-the-art HIV diagnostic technologies for CD4(+) T lymphocyte count, viral load measurement, and drug resistance testing are reviewed.
Journal ArticleDOI

The WHO public health approach to HIV treatment and care: looking back and looking ahead

TL;DR: Implementation of these key public health principles will bring countries closer to the goals of controlling the HIV epidemic and providing universal health coverage.
References
More filters
Journal ArticleDOI

Prevention of HIV-1 infection with early antiretroviral therapy

TL;DR: The exciting evidence generated by this paper – that antiretroviral treatment of HIV-1 infection definitively reduces the risk of onward transmission of the virus by 96% – was rightly dubbed Science magazine's ‘Breakthrough of the Year’ in 2011.
Journal ArticleDOI

Global epidemiology of hepatitis C virus infection

TL;DR: Because there is no vaccine and no post-exposure prophylaxis for HCV, the focus of primary prevention efforts should be safer blood supply in the developing world, safe injection practices in health care and other settings, and decreasing the number of people who initiate injection drug use.

Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision.

TL;DR: These guidelines are primarily intended for use by national and regional HIV programme managers managers of nongovernmental organizations delivering HIV care services and other policy-makers who are involved in the scaling up of comprehensive HIV care and ART in resource-limited countries.
Journal ArticleDOI

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients

TL;DR: In coinfected patients, a low CD4 count, alcohol consumption rate, and age at HCV infection are associated with a higher liver fibrosis progression rate, while HIV seropositivity accelerates HCV‐related liver Fibrosis progression.
Related Papers (5)